whats the criteria of the value of the exon-skipping development program outside DMD ( estimate is $100 million, the value of given the promise that it has shown in DMD) why $100mil
with the three products , i estimate an average net income of around $4 million , which represents valuation of around $40 million , provided all the three products are launched and sales are in line with the estimates in this article, we can expect a home run of about $4 per share based on the forward sales , 50% profit margin and revenues in total of abt $11 million.
Sell Facebook Down To $5: A Story Of Slashed EPS Estimates And Diminishing Visibility [View article]
Sarepta Therapeutics Looks Highly Undervalued [View article]
Time To Buy DARA Bio [View article]
2 Strategies For Making Extraordinary Returns With Apple Options [View article]